Emily G Greengard MD

Pediatric Hematology & Oncology•Chapel Hill, NC

Associate Professor, Pediatrics University of North Carolina at Chapel Hill

Join to View Full Profile

170 Manning Dr1185A Houpt Physicians Office BuildingChapel Hill, NC 27514
Phone+1 919-966-1179
Fax+1 612-365-8101

Education & Training

Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 2007 - 2010
McGaw Medical Center of Northwestern UniversityResidency, Pediatrics, 2004 - 2007
Saint Louis University School of MedicineClass of 2004

Certifications & Licensure

MN State Medical License 2010 - 2025
NC State Medical License 2024 - 2025
SD State Medical License Active through 2021
PA State Medical License 2007 - 2010
IL State Medical License 2004 - 2008
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
ACTIVE_NOT_RECRUITING
PHASE3
Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27
ACTIVE_NOT_RECRUITING
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2011 Sep 01
Completed
Phase 1
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12
Completed
Phase 2
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2013 Jan 31
Completed
Phase 1, Phase 2
MIBG for Refractory Neuroblastoma and Pheochromocytoma
SUSPENDED
NA
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Start of enrollment: 2013 Sep 03
Completed
Phase 1
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2014 Mar 28
Completed
Phase 1, Phase 2
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Start of enrollment: 2014 May 16
Completed
Phase 1, Phase 2
VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors Start of enrollment: 2014 Sep 01
Completed
Phase 1
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Start of enrollment: 2015 Dec 11
Completed
Phase 1
Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors Start of enrollment: 2018 Jan 31
COMPLETED
PHASE1, PHASE2
Join now to see all

Publications & Presentations

PubMed

Impact of the COVID-19 Pandemic Onset on the Early Careers of Pediatric Oncology Health Professionals and Researchers: A Report From the Children's Oncology Group Youn...
Gemma Bryan, Louise Guolla, Gabriela Inés Villanueva, Sarah Cohen-Gogo, Alejandra Casanovas
Pediatric Blood & Cancer. 2025-01-01
Population modeling analyses of crizotinib in pediatric patients with ALK-positive advanced cancers.
Li Jerry, Lin Swan, Nickens Dana, Frank M Balis, Emily Greengard
Pediatric Blood & Cancer. 2024-09-01
2 citations
A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL...
Emily Greengard, Robin Williams, Branden Moriarity, Xiaowei Liu, Charles G Minard
Pediatric Blood & Cancer. 2024-06-01

Lectures

A phase I/II trial of VX15/2503 in children, adolescents, and young adults with relapsed or refractory solid tumors (ADVL1614).
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019

Press Mentions

New Treatment for Central Nervous System Tumors Enters Phase I Clinical TrialsJanuary 12th, 2021